A Phase I/II Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase I/II Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Venetoclax (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 15 Nov 2017 Phase 2 has been added in to the study since treatment arms (3 to 4) and planned patients number are increases. Trial focus also changed.
    • 15 Nov 2017 Planned number of patients changed from 84 to 166.
    • 15 Nov 2017 Planned End Date changed from 26 Dec 2018 to 29 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top